Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 5, 2013, Pages 517-528

  Klimas, Romina ^a   Witticke, Diana ^a   El Fallah, Sarah ^a   Mikus, Gerd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

receptor; Blood brain barrier; Opioid; Oxycodone; Oxymorphone

Indexed keywords

AMITRIPTYLINE; CLARITHROMYCIN; CYTOCHROME P450 2D6; HYPERICUM PERFORATUM EXTRACT; IBUPROFEN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MORPHINE; OPIATE RECEPTOR; OXYCODONE; OXYMORPHONE; PAROXETINE; PLACEBO; QUINIDINE; RIFAMPICIN; TELITHROMYCIN;

ANALGESIC ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CONSTIPATION; DIZZINESS; DNA POLYMORPHISM; DRUG ANTAGONISM; DRUG METABOLISM; DRUG PENETRATION; GENOTYPE; HUMAN; NAUSEA; PRURITUS; SOMNOLENCE; VOMITING; XEROSTOMIA;

ANALGESIA; ANALGESICS, OPIOID; BLOOD-BRAIN BARRIER; BRAIN; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; GENOTYPE; HUMANS; MORPHINANS; OXYCODONE; OXYMORPHONE; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID;

EID: 84876361883     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.779669     Document Type: Article

References (55)

1. Falk E. Eukodal, ein neues Narkotikum. Münchner Medizinische Wochenschrift 1917;12:381-4
2. Mandema JW, Kaiko RF, Oshlack B, et al.Characterization and validation of a pharmacokinetic model forcontrolled-release oxycodone. Br J Clin Pharmacol 1996;42(6):747-56
3. Kaplan R, Parris WC, Citron ML, et al. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. J Clin Oncol 1998;16(10):3230-7
4. Parris WC, Johnson BW Jr, Croghan MK, et al. The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study. J Pain Symptom Manage 1998;16(4):205-11
5. Stambaugh JE, Reder RF, Stambaugh MD, et al. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. J Clin Pharmacol 2001;41(5):500-6
6. Salzman RT, Roberts MS, Wild J, et al. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? J Pain Symptom Manage 1999;18(4):271-9
7. Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 1999;15(3):179-83
8. Poyhia R, Vainio A, Kalso E. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 1993;8(2):63-7
9. Kalso E, Poyhia R, Onnela P, et al. Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 1991;35(7):642-6 1
10. Kapil R, Nolting A, Roy P, et al. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers. Clin Ther 2004;26(12):2015-25 1
11. Leow KP, Smith MT, Williams B, Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992;52(5):487-95 1
12. Mucci-LoRusso P, Berman BS, Silberstein PT, et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 1998;2(3):239-49 1
13. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E. Oxycodone: a pharmacological and clinical review. Clin Transl Oncol 2007;9(5):298-307 1
14. Poyhia R, Seppala T, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992;33(6):617-21 1
15. Leow KP, Cramond T, Smith MT. Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg 1995;80(2):296-302 1
16. Andreassen TN, Klepstad P, Davies A, et al. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol 2011;67(5):493-506 1
17. Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006;79(5):461-79 1
18. Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004;32(4):447-54 1
19. Kalso E, Vainio A, Mattila MJ, et al. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 1990;67(4):322-8 2
20. Cleary J, Mikus G, Somogyi A, Bochner F. The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. J Pharmacol Exp Ther 1994;271(3):1528-34 2
21. Samer CF, Daali Y, Wagner M, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol 2010;160(4):919-30 2
22. Samer CF, Daali Y, Wagner M, et al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 2010;160(4):907-18 2
23. Zwisler ST, Enggaard TP, Noehr-Jensen L, et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharmacol Toxicol 2009;104(4):335-44 2
24. Volpe DA, McMahon Tobin GA, Mellon RD, et al. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol 2011;59(3):385-90 2
25. Ing Lorenzini K, Daali Y, Dayer P, Desmeules J. Pharmacokinetic- pharmacodynamic modelling of opioids in healthy human volunteers. a minireview. Basic Clin Pharmacol Toxicol 2012;110(3):219-26 2
26. Liukas A, Kuusniemi K, Aantaa R, et al. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. Drugs Aging 2011;28(1):41-50 2
27. Liukas A, Kuusniemi K, Aantaa R, et al. Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharmacol Ther 2008;84(4):462-7 2
28. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998;64(6):603-11 2
29. Kaiko RF. Pharmacokinetics and pharmacodynamics of controlled-release opioids. Acta Anaesthesiol Scand 1997;41(1 Pt 2):166-74 3
30. Kaiko RF, Benziger DP, Fitzmartin RD, et al. Pharmacokinetic- pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996;59(1):52-61 3
31. Poyhia R, Olkkola KT, Seppala T, Kalso E. The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmacol 1991;32(4):516-18 3
32. Silvasti M, Rosenberg P, Seppala T, et al. Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta Anaesthesiol Scand 1998;42(5):576-80 3
33. Zwisler ST, Enggaard TP, Mikkelsen S, et al. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand 2010;54(2):232-40 3
34. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991;48(22):2165-71 3
35. Magnan J, Paterson SJ, Tavani A, Kosterlitz HW. The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn Schmiedebergs Arch Pharmacol 1982;319(3):197-205 3
36. Bostrom E, Simonsson US, Hammarlund-Udenaes M. In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos 2006;34(9):1624-31 3
37. Siegle I, Fritz P, Eckhardt K, et al. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 2001;11(3):237-45 3
38. Nieminen TH, Hagelberg NM, Saari TI, et al. St John's wort greatly reduces the concentrations of oral oxycodone. Eur J Pain 2010;14(8):854-9 3
39. Nieminen TH, Hagelberg NM, Saari TI, et al. Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. Eur J Clin Pharmacol 2010;66(10):977-85 4
40. Nieminen TH, Hagelberg NM, Saari TI, et al. Grapefruit juice enhances the exposure to oral oxycodone. Basic Clin Pharmacol Toxicol 2010;107(4):782-8 4
41. Nieminen TH, Hagelberg NM, Saari TI, et al. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 2009;110(6):1371-8 4
42. Biancofiore G. Oxycodone controlled release in cancer pain management. Ther Clin Risk Manag 2006;2(3):229-34 4
43. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990;47(5):639-46 4
44. Gronlund J, Saari TI, Hagelberg NM, et al. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol 2010;70(1):78-87 4
45. Gronlund J, Saari TI, Hagelberg N, et al. Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. Antimicrob Agents Chemother 2011;55(3):1063-7 4
46. Saari TI, Gronlund J, Hagelberg NM, et al. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol 2010;66(4):387-97 4
47. Liukas A, Hagelberg NM, Kuusniemi K, et al. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers. J Clin Psychopharmacol 2011;31(3):302-8 4
48. Kummer O, Hammann F, Moser C, et al. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol 2011;67(1):63-71 4
49. Hagelberg NM, Nieminen TH, Saari TI, et al. Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 2009;65(3):263-71 5
50. Gronlund J, Saari T, Hagelberg N, et al. Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. J Clin Pharmacol 2010;50(1):101-8 5
51. McFadzean I, Lacey MG, Hill RG, Henderson G. Kappa opioid receptor activation depresses excitatory synaptic input to rat locus coeruleus neurons in vitro. Neuroscience 1987;20(1):231-9 5
52. Bostrom E, Hammarlund-Udenaes M, Simonsson US. Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology 2008;108(3):495-505 5
53. Sloan P. Review of oral oxymorphone in the management of pain. Ther Clin Risk Manag 2008;4(4):777-87 5
54. Leow KP, Smith MT, Watt JA, et al. Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit 1992;14(6):479-84 5
55. Narabayashi M, Saijo Y, Takenoshita S, et al. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. Jpn J Clin Oncol 2008;38(4):296-304